What Oasis Diagnostics does

Oasis Diagnostics Corporation is a privately held, bootstrapped developer and manufacturer of non-invasive saliva and oral fluid collection devices and point-of-care testing tools, founded in 2002 and headquartered in Vancouver, Washington. The company sells Research Use Only (RUO) products spanning a portfolio of more than a dozen proprietary collection kits — including SuperSAL, SuperSAL 2, PureSAL, RNAProSAL, SimplOFy, DNA SAL, MicroSAL (for children and animals), AccuSAL, VersiSAL, FemCollect, and PediaSAL — engineered around a cylindrical absorbent pad architecture with a built-in Sample Volume Adequacy Indicator. Its VerOFy point-of-care platform pairs rapid saliva collection with immunochromatographic test strips and the LIAM Bluetooth-enabled portable reader for quantitative result capture. Beyond proprietary devices, Oasis generates distribution revenue as the exclusive North American distributor for ViennaLab Diagnostics assays (StripAssay and RealFast PCR products) and as authorized representative for Operon S.A. PCR-based genomic strip assays, and offers end-to-end custom product development services through a 23+ year partnership with Giddings Product Development.

The company's go-to-market combines direct B2B sales via its 4saliva.com catalog (with "Request Information" forms replacing public pricing) with channel partnerships for genomic assay distribution and emerging-market deployment, most recently through Oludent Health International across Africa, the Middle East, and Asia. Customer segments are horizontally diversified across diagnostics and biotechnology companies, contract research organizations, academic and clinical research laboratories, healthcare providers (including Alzheimer's Association NEWIDEAS and Worldwide FINGERS collaborations), and veterinary researchers. Oasis supplements device sales with an internal Oasis Research Lab offering fertility, steroid, and stress/fatigue biomarker panels (17β-estradiol, progesterone, testosterone, DHEA, DHEAS, cortisol, IL1β, TNF, IgA).

Oasis has issued patents across the US, EU, and international markets covering its oral fluid collection and testing products, and is led by CEO Paul Slowey. Recent strategic activity through 2025-2026 — including the SuperSAL 2 product launch, at-home cancer screening co-development with UCM Technologies, and the multi-party Tri-Engine Execution Model consortium for community health systems in Africa — signals an expansion from a niche RUO consumables vendor toward a platform player spanning consumer screening, emerging-market public health, and research tools, though all products remain research-use-only with no FDA-cleared diagnostic claims in the disclosed material.

Name

Oasis Diagnostics

Legal name

Oasis Diagnostics Corporation

Website

https://4saliva.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Oasis Diagnostics Corporation develops and manufactures proprietary non-invasive saliva and oral fluid collection devices (SuperSAL, PureSAL, RNAProSAL, VerOFy/LIAM) and distributes ViennaLab and Operon genomic assays in North America, serving diagnostics companies, research laboratories, and emerging-market health programs.

Ownership category

akta.pro rank

Product category

Diagnostic Sample Collection Devices

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Sample Collection, Stabilization & Pre-Analytics (biobanking, transport media, extraction kits) (HLAAALAM)

akta.pro secondary industries

Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)

Keywords

• Saliva collection devices
• Oral fluid diagnostics
• Point-of-care testing
• Molecular diagnostics tools
• Salivary biomarker research

Headquarters

HQ city

Vancouver

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Saliva Collection Device Sales: Sale of proprietary saliva and oral fluid collection devices including SuperSAL, PureSAL, RNAProSAL, DNA SAL, VersiSAL, SimplOFy, MicroSAL, AccuSAL, FemCollect, and PediaSAL kits. Products sold as Research Use Only (RUO).
2. ViennaLab Diagnostics Distribution: Exclusive distributor for ViennaLab Diagnostics products in Canada and United States, including StripAssay and RealFast PCR-based genomic kits for various diseases and conditions.
3. Operon S.A. Products Distribution: Authorized representative for Operon S.A. products including PCR-based genomic strip assays for celiac disease, HPV, and infectious diseases in US and Canada.
4. Custom Product Development: End-to-end development services from concept through production and packaging for custom saliva collection kits and testing tools, leveraging partnerships with Giddings Product Development.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Oasis Diagnostics develops, manufactures, and distributes proprietary saliva and oral fluid collection devices used in molecular diagnostics, proteomic analysis, and point-of-care testing. Its portfolio spans standardized collection kits (e.g., Super•SAL, Pure•SAL, RNAPro•SAL, DNA•SAL, SimplOFy, Micro•SAL, Accu•SAL, Versi•SAL, Fem•Collect, Pedia•SAL) plus the VerOFy® point-of-care platform with the LIAM™ Bluetooth reader. The company is also the exclusive North American distributor for ViennaLab Diagnostics genomic assays (StripAssay®, RealFast™) and the authorized US/Canada representative for Operon S.A. PCR-based genomic tests, and offers custom device development and salivary biomarker research services.

Product overview

Oasis Diagnostics® offers a comprehensive portfolio of non-invasive saliva and oral fluid collection devices for molecular, proteomic, and point-of-care diagnostics applications. The core product line includes standardized collection kits (Super•SAL 2™, Super•SAL™, Pure•SAL™, RNAPro•SAL™, SimplOFy™, DNA•SAL™, Micro•SAL™ for Children/Animals, Accu•SAL™, Versi•SAL®, Fem•Collect™, Pedia•SAL™) and the VerOFy®/LIAM™ point-of-care testing platform. The company also distributes ViennaLab Diagnostics genomic assays (StripAssay®, RealFast™) and Operon S.A. PCR-based products, while offering custom product development services and research lab biomarker panels for fertility, steroid, and stress biomarkers. All products are for research use only.

Differentiator

Problem solved

Functional benefit

Brands

• VerOFy®: Point-of-care platform for rapid saliva-based testing using lateral flow immunochromatography, latex agglutination, and magnetic beads
• LIAM™
• Versi•SAL®
• DNA•SAL™
• Super•SAL™
• RNAPro•SAL™
• Pure•SAL™
• SimplOFy™
• Accu•SAL™
• Pedia•SAL™
• Micro•SAL™
• Fem•Collect™
• ViennaLab
• Operon S.A.

Products and services

• Super•SAL 2™ Universal Saliva Collection Kit Universal saliva collection kit (Catalog Number SSAL-601) for standardized whole saliva sampling that collects ~1 mL in 1-5 minutes via a highly absorbent cylindrical pad placed along the side of the tongue. Built-in Sample Volume Adequacy Indicator and patented compression tube system; for research use only.
• Super•SAL™ Universal Saliva Collection Kit

Quantifiable outcome

• Products used by Alzheimer's Association NEWIDEAS study and Worldwide FINGERS Project for biomarker research
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• Oludent Health InternationalcoreStrategic or Co-development Partner · 24 November 2025Strategic partnership to expand saliva-based diagnostics in Africa, the Middle East, and Asia. Initiative aims to deploy early detection, point-of-care screening, and affordable testing solutions in emerging markets through the 360UNCOVER movement and Tri-Engine Execution Model.
• UCM TechnologiescoreStrategic or Co-development Partner · 10 November 2025Partnership to develop at-home saliva collection test for next-generation cancer screening. Combines Oasis saliva collection technology with UCM's biomarker assay CA-62 for early cancer detection. Initial validation studies planned for 2025-26.
• ViennaLab DiagnosticscoreChannel Partner/ Reseller/ DistributorExclusive North American distributor (Canada and United States) for ViennaLab Diagnostics assays including KRAS, BRAF, Alzheimer's, CVD, and pharmacogenomic tests based on StripAssay and RealFast PCR technologies.
• Operon S.A.majorChannel Partner/ Reseller/ DistributorAuthorized representative for Operon S.A. products in United States and Canada. Products include genomic strip tests for celiac disease, AZF micro-deletions, HPV, and infectious diseases (Chlamydia, HSV, Neisseria gonorrhoeae).
• Giddings Product Development (GPD)majorStrategic or Co-development PartnerLongstanding partnership since Oasis founding over 23 years ago. Led by Jason Giddings, providing deep technical skill and engineering precision for custom product development including design, CAD, prototyping, tooling, manufacturing, assembly, and packaging.
• Queensway Medical Training CollegecoreStrategic or Co-development PartnerConsortium partner in Tri-Engine Execution Model launched January 14, 2026 in Nairobi, Kenya. Partnership focuses on early detection, workforce development, and health system integration for community-based health systems in Africa.
• 360DisruptioncoreStrategic or Co-development PartnerConsortium partner in Tri-Engine Execution Model for scaling community-based health systems in Africa. Focuses on moving health innovation beyond pilots into scalable, country-level deployment with Kenya as first execution node.
• Dr. Elizabeth (Birdie) ShirtcliffminorOthersScientific advisor; Editor-in-chief of Psychoneuroendocrinology and research professor at University of Oregon. Longstanding collaborator with Oasis Diagnostics using noninvasive biospecimens including saliva for stress-responsive hormones research.
• Professor Chamindie PunyadeeraminorOthersScientific advisor; Innovator in salivary diagnostics and liquid biopsy laboratory at Griffith University for biomarker development from concept to commercialization. Leading women's health and precision health research.
• Dr. Chi Udeh-MomohminorOthersScientific advisor; Translational Neuroscientist at Wake Forest University School of Medicine. Founding Chair of Saliva Biomarkers for Dementia Research workgroup (Alzheimer's Association ISTAART). Co-Leads World-Wide FINGERS Biomarker Consortium.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• OraSure Technologies: Pioneer in oral fluid collection and rapid diagnostics (Intercept, OraQuick). Competes with Oasis in saliva-based specimen collection and infectious disease/point-of-care testing.
• MAWI DNA Technologies: Maker of iSWAB collection kits — Oasis is an existing distribution partner for the iSWAB Microbiome kit. Directly comparable in non-invasive sample collection products and applications.
• Salimetrics: Saliva-based biomarker testing lab and saliva collection device provider (SalivaBio). Closely comparable in salivary biomarker discovery services and collection devices for stress/hormone research.
• Spectrum Solutions: Saliva collection device manufacturer (SDNA-1000) used widely for COVID-19 and genetic testing. Direct comparable in product, regulatory positioning, and molecular diagnostics customer base.
• DNA Genotek (Oracle Health): Direct competitor in saliva-based DNA/RNA collection devices (Oragene, ORAcollect). Most directly comparable in product, customer base (research/diagnostics), and geographic focus.

Broad incumbents

• Neogen Corporation: Animal and food safety diagnostics with emerging genomics offerings. Comparable through veterinary diagnostics use cases (MicroSAL for Animals) and broader diagnostics distribution model.
• Roche Diagnostics: Major IVD platform with broad molecular diagnostics, oncology screening, and saliva-based test offerings (e.g., cobas). Relevant comparable as scale-of-execution benchmark for Oasis's emerging at-home cancer screening ambitions.
• QIAGEN: Large established provider of sample technologies and molecular diagnostics. Overlaps with Oasis in pre-analytical/sample collection consumables across PCR, sequencing, and IVD workflows.
• Thermo Fisher Scientific: Diversified life sciences tools and diagnostics leader. Comparable in sample collection/pre-analytical consumables, molecular diagnostics kits, and laboratory equipment across research and clinical channels.

Others

• ViennaLab Diagnostics: Oasis is the exclusive NA distributor for ViennaLab's StripAssay and RealFast PCR kits. As a supplier-partner rather than direct competitor, ViennaLab is an ecosystem comparable for molecular diagnostics kit manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oasis Diagnostics